ABSTRACT
To evaluate success with intravitreal injection of ocriplasmin in releasing symptomatic vitreomacular traction [VMT]. A retrospective review of consecutive series of patients in a single vitreoretinal practice. Patients with symptomatic distortion and loss of vision secondary to VMT were included in the study. Patients received a single injection of ocriplasmin [JETREA] and were followed-up after 1 month with optical coherence tomography. Eight patients [8 eyes] were included [2 males and 6 females] in the study. Five of 8 eyes [62.5%] experienced complete release of the VMT; one of 8 eyes [12.5%] had partial release of VMT and two of 8 eyes [25%] did not have release of VMT. The two patients with no release of their VMT had the same vision. Of the 5 patients with complete release of VMT, 3 patients had a one line worsening of their vision, 1 had a 4 line improvement of vision, and 1 stayed the same. The patient with only partial release of their VMT had a 1 line worsening of vision. Intravitreal ocriplasmin is a promising treatment option for vitreomacular traction syndrome in symptomatic patients